Member Info for chester18

Agreed but why are you so sure it’s a Poster rather than a 15 mins Presentation.

The Session is listed as :

Late Breaking Research - Clinical Research 1

From 2:00pm until 5:00pm

That is not a Poster Event. So my suggestion that it could be the beginning of some data being shared does have possibilities does it not ?

Scinv

Where did you read that it is just a Poster.

You don’t usually make things up

Morning Scinv

I’ve just checked the RNS Announcement and the word ‘Poster’ does not seem to be in there.

Anyhow this is a possibility :

Interim Report 30th Jan 2025 states that 25 week ORR data from SCIB1 plus CPI’s expected mid-2025.

If we call Thursday 10th July Mid-year and retrace 12 weeks to Thursday 17th April that is when the 13 week scan data could be available. That still allows time to verify and Present at AACR on the 28th.

So there is a possibility that 13 week ORR data for a complete Cohort 1 could be released just prior to that conference.

Is this pointing to up to date data released ?

‘Scancell CMO Nermeen Varawalla will present the SCOPE clinical trial program, preliminary results of cohort 1 and their correlation with T cell responses. These data along with those expected from ongoing study cohorts, 3 & 4 will determine the design for the planned follow-on randomised registration clinical trial’.

‘Preliminary Results’. ??

The market, or another way of putting it, the combined consciousness of potential investors, is fickle. We call it ‘Sentiment’.

Any company that is not creating a profit today, is seen as risky in the eyes of this markets current sentiment.

Scancell is, via two clinical trials, building platforms that may radically alter the direction and future of cancer treatments.

Namely, Cancer Vaccines.

As I’ve said before Scancell is a pioneer.

The results from our trials will determine the future value of the company and therefore a rise in the share price.

Through the trial results so far and having a rough understanding of what it is Scancell’s Tech actually does, I believe the outcome will be a vaccine that saves the lives of many stage 4 melanoma cancer patients as a starting point.

The current price is an opportunity for anyone who believes that the data arriving in about 5 months will be transformative.

I don’t discount the concerns that we have as shareholders in this current economic climate. Also AIM seems have gone nearly ‘all in’ as a traders market rather than any chance of a fair and reasonable place for a long term investment.

However, Scancell is not a one trick pony and there is a vast amount of new clinical science evolving within their walls.

The acid test for Scancell’s SCOPE Trial is to pass all the data hurdles by the beginning of Q4/25.

Is iSCIB+ on par or better than SCIB1 ?

Is an Intradermal PharmaJet delivery measurably better or worse than intermuscular. These fundamental issues need to be resolved at the same time.

That will then be enough information for any willing partner to make the decision to join Scancell and provide the financial muscle needed to drive the registration trial.

This must be of paramount importance to the Board of Directors and I’m sure their combined efforts will be focused on achieving that goal.

I’m definitely not a paid ramper but I would like to point out

‘why RNS an update today’ ?

It’s the 19th with a good chunk of the month to go. If this was an attempt to cover up for the lack of any news on a JV, why so early ?

Sternship Advisors PTY

“Sternship Advisers is a ‘boutique’ Perth-based advisory firm established in mid-2017 by the former UBS Perth team”.

Hopefully no more than 11 months…..

What we need is solid data from SCOPE cohorts 3 & 4 opening the way for the Reg Trial. That should be enough to attract a partner. Then we are on our way.

If none of the above happens we would be in a bit of a mess. Not down and out, just a ‘messy mess’ because we will still have MODI1, GlyMabs and AvidiMab to fall back on but it would mean a further dilution and a much reduced share price, until ModiFY reads out. 😳

Come on Dracula1

We’ve had this conversation a few times now. Those ‘other’ pre-clinical deals are for well understood and commercially valuable products.

Scancell are pioneers in the field on Cancer Vaccines. So data / proof first then a deal.

Let’s just wait and see if 2025 does bring that long awaited partnership.

Hi MBUski

Cancer Vaccines are still viewed with caution by the large pharmaceutical companies. Both Lindy Durrant and our new CEO have both said that value will only come from the quality of the trial data. Early concept and small patient size results do not count for much other than keeping those with the big cash piles interested.

The SCOPE data that should arrive end of Q3 will cover SCiB1 plus Double Checkpoints, iSCiB+ plus CPI’s intramuscular and iSCIB+ plus intradermal.

That will represent a trial data set from a larger patient population. Data that large pharma can make a decision against.

Our investment in Scancell will be defined by all the data landing in 2025. Will a partnership be cemented ?

Scinv is right, no one can accurately predict how long the next phases will take.

However Scancell have given enough information on timelines for a best scenario as follows:

ISCIB+ data will be available August, September time. A decision will then be made as to which version goes forward to a randomised phase 2/3 adapted SCOPE registration trial. That trial could be underway by May 2026, the trial will complete in 18 months, results approx November 2027.

At that point if the trial results are positive we would need a Pharma partner but we would have a product going towards commercialisation. I would presume the final stage would be a larger phase 3 trail.

So fully commercial and income being generated in 2029 / 2030.

As a guess ……. 🤔

Interesting that the Potency Assay has been developed using iSCIB+ with no mention of SCIB1.

Certain details concerning iSCIB+ suggest it is going to be the upgraded version of Immunobody going forward. We can also see that a lot of research resource is going into iSCIB+.

We were told by RNS on 18-11-24 that just one more HLA-A2 patient was needed to complete the SCIB1 cohort 3. The recruitment of cohort 4 had reached 33, as stated in the same RNS. That left 10 patients to enrol and I am presuming that the majority will be the necessary HLA-A2 part of the 43 total.

This new information about the development of the Potency Assay leads me to conclude that the early scan data from iSCIB+ has shown to be as good or ( fingers crossed ) better than SCIB1.

This also means that I do expect all HAL-A2 patients in cohort 4 to do just as well as they did in cohort 3. There doesn’t seem to be any scientific reason why they would not.

The $64M question :

It’s the coming trial data that will determine whether Scancell’s value rockets or plods on.

We need the SCOPE data to be better than ‘just good enough’. I think if iSCIB+ matches SCIB1 across 100% of potential patients rather than the current 30% then we might be into ‘outstanding’ territory.

The data has to be strong enough to point clearly towards a profitable, highly commercial and competitive cancer treatment. That is what will attract a large pharma partner.

The jewel in the crown would be if Modi1 plus double checkpoint in out Renal Cell Carcinoma cohort also produces early outstanding Overall Response Rates. That would throw the doors open to Modi plus CPI’s trials in other solid cancers. Ovarian could be a good place to start as our Mono results were mainly ‘stable’.

So much yet achieve but this all hinges on Solid, Positive data from cohorts 3 and 4 of the SCOPE trial.

As one of my Lancashire mates once pointed out to me : ‘Foam wasn’t spilt in a Tray’.

A true philosopher…….

SCiB1 Mono Cohort1 started on 19th October 2019. Cohort 2, the addition of Keytruda, 1st patient dosed 18th November 2021.

Trial expanded to Cohort 3 with Double Checkpoints on 15th June 2022. This means that cohort 3 will have been running for 3 years in June this year.

One of the main criteria for measuring success in the Registration trial is the Overall Survival Rate. Considering we are mainly treating stage 4 cancer patients our OSR will be of great importance to any potential partner.

When the data from SCOPE is presented I expect it to be linked to a partnership or overall deal for the Immunobody Platform.

Hi C11

I emailed to ask about the neoadjuvant cohort because in the Trinity Delta report the Modi Mono arm ( 15 patients) had a tick against it but the Modi plus CPI didn’t.

The reply received early February was that Modi Mono was complete and Modi1 plus CPI was still recruiting. No number given so I’m guessing that we are still a few months away yet.

When will there be some positive share price moving news?

The one piece of news I thought would have landed by now is the ‘GenMab in the Clinic’ with our GlyMab. So that one could be anytime.

Trial data from any one cohort across SCIB1, iSCIB+ or Modi1 all seem to be converging towards late Summer.

With no impending cash requirements will we hear about early data. I’m thinking about the early ORR data that was released from SCIB1 plus Double Checkpoint.

My thoughts are we will not hear anything about partial trial data. So unless there is something amazing from Left Field I suggest we try to ignore the current price movements and enjoy the next 4/5 months.

The data that is slated to arrive end July / early August will define our investment.

Hi Cleanerworld

Yes I remember Lindy saying those exact words.

There is always another layer to Scancell and when we eventually find out where the edge cases are up to we get an insight into just how deep the team’s knowledge and understanding is of our immune system.

Onwards and upwards……… 🖖

Illumina have already seen the potential of offering dual CtDna and CTCDna analysis from the same tube of blood. As the economics filter through to those that matter we will see a significant increase in the interest of Angle PLC.

The change will take time but the Blood Biopsy market will realise the benefits of dual analysis. Thus enabling more accurate and timely drug prescription and critically leading to higher patient outcomes / money spent per successful outcome.

To start the process we need the follow on Pharma contracts to be signed and announced.

Https://news.sky.com/story/life-saving-simple-blood-test-could-transform-and-personalise-cancer-care-if-trial-succeeds-13313872